Skip to main content
Login
Contact
Subscribe
Search form
Search
The Punxsutawney Spirit
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Local Guide
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Gilead Sciences
(NQ:
GILD
)
66.77
USD
-0.86 (-1.27%)
Streaming Delayed Price
/ Updated:
8:22 AM EST, Dec 13, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
17,796
Open
67.63
Bid (Size)
66.90 (8)
Ask (Size)
66.98 (1)
Prev. Close
67.63
Today's Range
66.69 - 67.63
52wk Range
60.32 - 70.50
Shares Outstanding
1,300,260,832
Dividend Yield
3.34%
Performance
YTD
+5.25%
+5.25%
1 Month
+3.81%
+3.81%
3 Month
+0.62%
+0.62%
6 Month
-0.33%
-0.33%
1 Year
-2.01%
-2.01%
Top News
More News
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
December 11, 2019
Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta
Read More
from
GlobeNewswire News Releases
Kite Submits Biologics License Application to U.S. Food and Drug Administration for Company’s Second CAR T Cell Therapy
December 11, 2019
Kite, a Gilead Company (Nasdaq: GILD), today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the investigational chimeric...
Read More
from
Business Wire News Releases
More News
Read More
Kite and Kiniksa Pharmaceuticals Announce Clinical Collaboration Evaluating Investigational Combination of Yescarta® and Mavrilimumab in Relapsed or Refractory Large B-Cell Lymphoma
December 11, 2019
from
Business Wire News Releases
Kite and the CIBMTR® Present Positive Findings From Real-World Use of Yescarta® (Axicabtagene Ciloleucel) in Relapsed or Refractory Large B-Cell Lymphoma
December 09, 2019
from
Business Wire News Releases
Kite Presents Positive Results From Pivotal ZUMA-2 Trial in Relapsed or Refractory Mantle Cell Lymphoma
December 09, 2019
from
Business Wire News Releases
We Did The Math PJP Can Go To $72
December 12, 2019
category
ETFs
from
ETF Channel
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment
December 07, 2019
from
Business Wire News Releases
Noteworthy Wednesday Option Activity: GILD, GKOS, DERM
December 11, 2019
category
Stocks
from
Market News Video
Hot Options Report For End Of Day - Wednesday, Dec. 11
December 11, 2019
category
Options
from
Blogs - TalkMarkets
Investors shift attention to next generation of CAR-T, new sickle cell treatments at major hematology meeting
December 10, 2019
category
GBT
,
GILD
,
General
, and 7 more.
from
MarketWatch
No CRISPR Required: This Forgotten Gene Editing is Up 50% in 5 Weeks
December 09, 2019
category
Market News
,
CRSP
,
BYND
, and 3 more.
from
Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.